T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

Slides:

Advertisements

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Advertisements

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Antibody Independent Microfluidic Cell Capture of Circulating Tumor Cells for the Diagnosis of Cancer Eric Lim, MB, ChB, MD, MSc, FRCS, Andee Tay, BSc,

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

SC17.02 Lung Cancer in China: Challenges and Perspectives

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients Antonio Marchetti, MD, PhD,

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma Filippo Gustavo Dall’Olio, MD, Celeste.

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy Sotirios Lakis,

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer Suzanne Jenkins, DPhil, James C-H.

A Novel EGFRC797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture–Based Next- Generation.

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Circulating tumor DNA: Solid data from liquid biopsies

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Frank Detterbeck, MD Journal of Thoracic Oncology

Tumor Cell Content for Selection of Molecular Techniques for T790M EGFR Mutation Detection in Non-small Cell Lung Cancer Nathalie Prim, Elisabeth Quoix,

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients Jangchul Park, MD, Chiaki Kondo, MD, Junichi.

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

Reliability Assurance of Detection of EML4-ALK Rearrangement in Non–Small Cell Lung Cancer: The Results of Proficiency Testing in China Yulong Li, MD,

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping Sai-Hong Ignatius Ou, MD, PhD,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

VATS Thymectomy with 3D Vision: A Chance to Further Improve the Outcomes of Thymus Minimally Invasive Surgery Federico Attene, MD, Fabrizio Scognamillo,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Jamie A. Saxon, PhD, Lynette M. Sholl, MD, Pasi A. Jänne, MD, PhD

Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung.

Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib

Successful Treatment with Gefitinib in Advanced Non–Small Cell Lung Cancer after Acquired Resistance to Osimertinib Nuria Chic, MD Journal of Thoracic.

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

First Case of A859T Epidermal Growth Factor Receptor Mutation Responding to Erlotinib Laureline Le Maignan, BM, Delphine Mirebeau-Prunier, MD, PhD, Laurent.

Chien-Wei Chen, MD, Chin-Wei Kuo, MD Journal of Thoracic Oncology

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

It’s All in the “Swerve of the Curve”

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer Hiroaki Ogata,

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Rapid Detection of Hotspot Mutations in Epidermal Growth Factor Receptor by Polymerase Chain Reaction Facilitates the Management of Non-small Cell Lung.

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

International Thymic Malignancies Interest Group: A Way Forward

European Lung Cancer Conference (ELCC) 2016 Organisation

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Successful AZD9291 Therapy Based on Circulating T790M

IASLC 6th Latin American Conference on Lung Cancer

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

Two Rare Exon 21 EGFR Mutations in Patients Treated with Gefitinib

Robert Comis, MD, The Passing of a “Lung Man”

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais, MD, Catherine Daniel, MD, François-Clément Bidard, MD Journal of Thoracic Oncology Volume 12, Issue 9, Pages e138-e139 (September 2017) DOI: 10.1016/j.jtho.2017.04.022 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Methods of detecting circulating tumor DNA in blood and cerebrospinal fluid (CSF). PCR, polymerase chain reaction; VAF, variant allele frequency; NGS, next-generation sequencing. Journal of Thoracic Oncology 2017 12, e138-e139DOI: (10.1016/j.jtho.2017.04.022) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions